Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
about
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusCardiovascular Risk in Diabetes Mellitus: Complication of the Disease or of Antihyperglycemic MedicationsSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesThe alliance of mesenchymal stem cells, bone, and diabetesRenal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsUpdate on the treatment of type 2 diabetes mellitusSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureBenefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-AnalysisEffects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study.Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis of randomized controlled trials.Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus.A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapyA Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesThe influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.Dapagliflozin efficacy and safety: a perspective review.Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.DapagliflozinDapagliflozin for the treatment of type 2 diabetes: a review of the literatureEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trialSodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsDapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Dapagliflozin in patients with type 2 diabetes mellitus.Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trialsThe efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the potUpdate on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitusGlucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesSGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'
P2860
Q26782225-019564D4-4938-4B4F-8027-1E9E38508F4DQ26824616-7AFD6A57-4BDB-4747-AC15-3D7C9F5313B1Q26864336-59C55129-8EA4-4BAA-BA44-3768BD224408Q27012497-75770AFF-82EF-47DC-BB1E-BA2CA7B02366Q27027105-12D6667F-CF5C-4328-BC6B-6AECADBC44D1Q28072765-A0DA25C7-AED2-4A5C-B2FD-0384BF398F4DQ28073342-33D281DC-77A7-4AAB-AC84-DCD6F8E34474Q28074843-99725618-4AC1-47D4-9A1A-EC90F9E20A64Q28080114-7EB8C24D-B991-40A3-88F1-1494405E1D35Q28553482-8B48F051-46B9-4D96-BAC9-1C9785769F08Q30248634-3F620885-9EB9-4199-B8F6-8C56D32F7D3DQ30663494-72C9F818-2864-4838-A6B4-FE3A6E71D0BFQ30833760-F0383385-EB4E-40B5-A285-0B0521895A2CQ30877953-7963093B-F5C4-42E0-8126-45AB50EA2DE0Q33166813-9EA72E4E-D37C-4F1A-B3A5-F88EF30D17FEQ33732583-E7D07D51-E333-4D20-ABB2-7B0A2214F432Q33760535-828825A2-E0B9-4DA0-8B06-C54C9F5637F2Q33785128-CB4D3508-B0D6-4A9B-95BB-5CA7DE1DB351Q33859245-F6E5386B-BEED-4372-A6B5-17525BE6FD4BQ34161881-36E98AD3-7FE2-47B3-85B9-18E3AD639BA3Q34198692-9C3F2755-1033-45FB-9ECE-3AC7013C2EBDQ34315521-0D867925-89FD-4147-BBC3-1472E37655AAQ34453811-60B7D700-15CF-48F9-8C8D-066FE3FD3272Q34514280-0D875567-7321-495C-AFF1-058366415EDBQ34543009-BD5D5566-600E-406F-82C5-11D2BFB5FC51Q34593046-6DC6B381-3576-4314-B52D-92A711BBCD96Q34613015-CB794126-5E13-4F38-A678-C02D3AFCFE15Q34710819-A74C8B85-9B26-41D7-9A3B-72F9C1CD27B7Q34804900-A5B0B278-3885-424B-BFED-C3DAA429A600Q34973750-6927D7BC-3923-41CB-AD8F-A192A36EB58DQ35014111-AB3963BB-3384-4002-A88D-B869F1597B36Q35064363-50A81698-E504-4C6C-BDB6-0DEB69C73953Q35068181-6A2E72F4-4EF4-43CD-A9C1-39B1D92142A4Q35141884-BE8483FF-3A4F-4738-A60F-EB60CFF01C4BQ35192356-69105408-0690-4419-8D62-9E4925F0E9E4Q35528766-46C449A4-CC8C-4CA9-8DE1-BD11A4C0030CQ35780861-A2286EFF-9615-4DD8-8FE6-73664CFE5FD1Q35906490-F3D6D4AD-E302-4A03-80A0-3A2F898BC2B4Q35973288-A9A1609B-18A7-4818-8C51-C0B101B63316Q36073447-442E57D0-D886-4672-9BAC-E1E09FB0AA25
P2860
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Effects of dapagliflozin, an S ...... d on pioglitazone monotherapy.
@ast
Effects of dapagliflozin, an S ...... d on pioglitazone monotherapy.
@en
type
label
Effects of dapagliflozin, an S ...... d on pioglitazone monotherapy.
@ast
Effects of dapagliflozin, an S ...... d on pioglitazone monotherapy.
@en
prefLabel
Effects of dapagliflozin, an S ...... d on pioglitazone monotherapy.
@ast
Effects of dapagliflozin, an S ...... d on pioglitazone monotherapy.
@en
P2093
P2860
P356
P1433
P1476
Effects of dapagliflozin, an S ...... d on pioglitazone monotherapy.
@en
P2093
Afshin Salsali
James F List
Marisa Vico
P2860
P304
P356
10.2337/DC11-1693
P407
P577
2012-03-23T00:00:00Z